Novel therapeutic agents in Waldenström's macroglobulinemia
- PMID: 19362982
- PMCID: PMC3133646
- DOI: 10.3816/CLM.2009.n.022
Novel therapeutic agents in Waldenström's macroglobulinemia
Abstract
Within the past few years, major advances in the preclinical and clinical testing of novel therapeutic agents have occurred in Waldenström's macroglobulinemia (WM). These include agents that target the PI3K/Akt/mTOR pathway, PKC pathways, NF-kB signaling pathway, as well as tyrosine kinases and histone deacetylase inhibitors. In this review, we summarize the current understanding of the clinical development of these agents in WM.
References
-
- Ghobrial IM, Gertz MA, Fonseca R. Waldenstrom macroglobulinaemia. Lancet Oncol. 2003;4:679–685. - PubMed
-
- Dimopoulos MA, Kyle RA, Anagnostopoulos A, et al. Diagnosis and management of Waldenstrom's macroglobulinemia. J Clin Oncol. 2005;23:1564–1577. - PubMed
-
- Treon SP, Dimopoulos M, Kyle RA. Defining Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30:107–109. - PubMed
-
- Treon SP, Gertz MA, Dimopoulos M, et al. Update on treatment recommendations from the Third International Workshop on Waldenstrom’s macroglobulinemia. Blood. 2006;107:3442–3446. - PubMed
-
- Vijay A, Gertz MA. Waldenstrom Macroglobulinemia. Blood. 2007;109:5096–5103. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous